B-type natriuretic peptide and severe heart failure at baseline predict overall mortality in incident dialysis patients

Clinical Nephrology

Volumn 73, Issue 1, 2010, Pages 21-29

  Koch, M ^a,d   Trapp, R ^a   Kohnle, M ^a   Aker, S ^a   Haastert, B ^b   Rump, L C ^c  

^a Center of Nephrology   (Germany)

^b Medistatistica   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d NONE   (Germany)

Author keywords

B type natriuretic peptide (BNP); End stage renal disease (ESRD); Incident hemodialysis (HD); Mortality

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN;

ANGINA PECTORIS; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PROGNOSIS; SINUS NODE; SURVIVAL RATE;

EID: 74049136518     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73021     Document Type: Article

References (27)

1. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005; 112: 1121-1127.
2. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002; 105: 2392-2397.
3. Capelli JP, Kushner H. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results. Hemodial Int. 2008; 12: 450-462.
4. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N et al. Arapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001; 37: 386-391.
5. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007; 50: 2357-2368.
6. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006; 175: 611-617.
7. Gmar-Bouraoui S, Skhiri H, Achour A, Frih A, Dhia NB, Hammami S et al. The predictors of early mortality in patients starting chronic hemodialysis. Saudi J Kidney Dis Transpl. 2003; 14: 23-29.
8. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM et al. Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007; 49: 1114-1119.
9. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005; 46: 1-82.
10. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. Second Edition ed. New York, NY: Wiley & Sons, Inc.; 2002.
11. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol. 2006; 97: 1530-1534.
12. Koch M, Haastert B, Trapp R. The prognostic value of the C-reactive protein levels in HD patients with death risk from infection. Clin Nephrol. 2007; 68: 18-25.
13. Koch M, Trapp R, Kulas W, Grabensee B. Critical limb ischaemia as a main cause of death in patients with end-stage renal disease: a single-centre study. Nephrol Dial Transplant. 2004; 19: 2547-2552.
14. Lachin JM. Biostatistical methods: the assessment of relative risk. New York, NY: John Wiley and Sons, Inc.; 2000.
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18: 1440-1463.
16. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998; 32: 853-906.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
18. Magga J, Vuolteenaho O, Tokola H, Marttila M, Ruskoaho H. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med. 1998; 30 (Suppl): 39-45.
19. Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002; 22: 437-444.
20. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996; 28: 22-30.
21. Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from theADEMEXtrial. Clin J Am Soc Nephrol. 2008; 3: 407-415.
22. Postorino M, Marino C, Tripepi G, Zoccali C. Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant. 2007; 22: 1377-1382.
23. Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters WL Jr et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation. 1981; 64: 744-753.
24. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005; 16: 1788-1793.
25. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3: 1644-1651.
26. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2007; 18: 321-330.
27. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001; 12: 1508-1515.